Ben Okonkwo: Jonathan, good to be back — how was your week, genuinely?
Jonathan Ingles: Long. But weirdly productive — I went down a longevity rabbit hole that I cannot recommend to anyone who values their sleep.
Ben Okonkwo: Now I'm interested. What triggered it?
Jonathan Ingles: ScienceAlert ran a piece on a review — Shaima Ibrahim, American University in Cairo, published in Discover Public Health. 55 years of research, 124 studies. And the conclusion was no universal formula for reaching a hundred. I read that and thought — okay, that should end the longevity industry. Instead it's Tuesday morning newsletter content.
Ben Okonkwo: So the research's own humility is being recruited as a sales pitch.
Jonathan Ingles: Exactly — but the part that actually got me is more specific than that. Everyone talks about centenarians as if they've slowed their clocks down. That's the operating assumption behind every supplement, every protocol. And that's just wrong.
Ben Okonkwo: Wrong in what direction?
Jonathan Ingles: They age at a completely normal rate. The data says they're not doing anything exceptional for most of their lives. What they're doing is not contracting the diseases — cardiovascular disease, cancer — that kill most people in their 80s. They're delaying those by 15 to 20 years. That's the mechanism. Not anti-aging. Disease avoidance.
Ben Okonkwo: Okay — that's actually a significant reframe. Because compression of morbidity points at the same thing from the other end: the decline, when it comes, is compressed into a shorter window. So it's not that they're always healthy. It's that they're sick for less of their life, and later.
Jonathan Ingles: And one in five thousand Americans is already living that pattern right now. That's what we're trying to understand today — and frankly, the gap between what 124 studies tell us and what gets sold on the back of them is the whole story.
Ben Okonkwo: And that disease-avoidance pattern — that's where the genetics story gets genuinely strange. Think of it like a combination lock with 281 dials. Each dial barely matters on its own. But to reach a hundred, you probably need most of them pointing the right way simultaneously. That's what Thomas Perls and the New England Centenarian Study actually found. Two thousand people, tracked over decades, starting in the 1990s — 281 genetic markers, 27 genetic signatures. Not one longevity gene. Hundreds of variants, each with a modest individual effect, collectively doing something enormous.
Jonathan Ingles: So where does that leave lifestyle? If it's 281 dials, can I even touch any of them?
Ben Okonkwo: Right — and that's the uncomfortable answer. Probably not most of them. Now, here's what makes this concrete: Paola Sebastiani, who co-authored the foundational genetics work with Perls, showed that children of centenarians have measurable survival and health advantages over population controls. The heritable signal is strong enough to show up in the next generation. That's not lifestyle. That's something being passed down.
Jonathan Ingles: Wait — so the offspring advantage. That's the cleanest evidence that genetics is doing heavy lifting, not the supplement stack.
Ben Okonkwo: It's the clearest signal we have, yes. And it raises a real problem for — actually, let me back up — the framework here is multifactorial aging. Genetics, lifestyle, environment, socioeconomic conditions all interact. Nobody serious is saying lifestyle is zero. But when you're talking about the extreme tail — centenarians, semi-supercentenarians — the genetic architecture looks like it's doing the heavy lifting in ways that no morning routine can replicate.
Jonathan Ingles: No, I don't buy that as a clean split.
Ben Okonkwo: Go on.
Jonathan Ingles: The centenarian offspring advantage — frankly, those children also tend to have better healthcare access, higher socioeconomic status. We're calling it genetics when it might be privilege running across generations. The motive to label it heritable is obvious: it lets wealthy people believe their longevity is earned through good genes, not good circumstances.
Ben Okonkwo: That's a real confound — survivorship bias runs through the whole methodology too, not just the offspring data. But the genetic signal does hold up in studies that try to control for socioeconomic status. It's not eliminated by the confound. It's complicated by it.
Jonathan Ingles: Okay. So how much can lifestyle actually move?
Ben Okonkwo: Rough figure from the genetics literature: exceptional longevity — reaching a hundred — is maybe twenty-five percent attributable to heritable factors. Which sounds like lifestyle has seventy-five percent of the room. But here's where that number misleads: the twenty-five percent that's genetic is almost certainly nonlinear. It's not that genetics contributes a quarter of the distance. It's that without a particular polygenic profile, the ceiling is simply lower — and no behavioral intervention gets you past it.
Jonathan Ingles: So the wellness industry is selling you movement on dials that, for most people, are already fixed.
Ben Okonkwo: Probably far less movement than advertised. Not zero — but the honest version of what the New England Centenarian Study actually shows is that we've identified 281 markers and still can't build a formula. That's not a research gap we're about to close. That's the structure of the problem.
Jonathan Ingles: But the dial metaphor actually obscures something important — because the question isn't how many dials you can move. It's which dials you're even trying to turn. And I think most people are turning the wrong ones entirely.
Ben Okonkwo: Say more.
Jonathan Ingles: Picture someone's grandmother at 97 — still cooking Sunday dinner, sharp, mobile, running her own household. Then four months later she's gone. That's not a sad story about decline. That is the pattern. That is compression of morbidity working exactly as described. She didn't slow down for years. She just... didn't fall off the cliff until very late, and then she fell fast.
Ben Okonkwo: Right — and that's the thing I need to complicate. Because that grandmother is the version we remember, and she's real, but she's not the whole picture. Some centenarians do live long with extended disability. The compression of morbidity pattern holds for a meaningful subset, not — and this matters — not a guaranteed outcome for everyone who reaches a hundred.
Jonathan Ingles: Which is survivorship bias doing exactly what it does.
Ben Okonkwo: Precisely. We're only studying people who made it. So when the Ibrahim review documents this compressed-decline trajectory, we genuinely cannot fully separate — I mean, is that a feature of how those individuals aged? Or is it partly just what surviving to a hundred looks like, statistically, in people who were already biologically robust enough to get there?
Jonathan Ingles: Hold on. That actually reframes what the goal should be.
Ben Okonkwo: How so?
Jonathan Ingles: Look — if compression of morbidity is the thing we actually want, then the research goal isn't 'live longer.' It's 'decline faster and later.' Those are different targets. And the wellness industry is selling the first one. Nobody's Saturday morning newsletter is titled 'how to have a four-month decline at 97 instead of a four-year one at 83.' But frankly, that's the more defensible ask. That's what the Ibrahim review's data actually supports as a population-level ambition.
Ben Okonkwo: Population-level being the load-bearing phrase there. Because — and this is where the honest version gets uncomfortable — you can't promise any individual person the compressed-decline trajectory. Even if it's real, even if it's documented across the 124 studies. It's a pattern in a group that already survived. It cannot be individually guaranteed.
Jonathan Ingles: Right. But that's a policy argument, not a reason to do nothing.
Ben Okonkwo: Agreed — and what that means practically is the target for aging research should shift. Not 'add years' but 'compress the tail.' That is a different intervention design entirely. Different endpoints in trials, different metrics for success. The field hasn't fully made that turn.
Jonathan Ingles: And when we get to what Ibrahim's review actually concludes — no universal formula — and then watch how that conclusion gets converted into prescriptive advice anyway, it gets genuinely ugly. We'll get there. But the morbidity reframe is what should make someone read those headlines completely differently.
Ben Okonkwo: And that conversion — from 'no formula exists' to 'here's your formula' — that's actually where the Ibrahim review becomes, I mean, almost useful as a case study in how this machine works structurally.
Jonathan Ingles: The machine being the wellness industry specifically.
Ben Okonkwo: Right — and not through malice. Through format. ScienceAlert covers the review and the format of a news article invites a list of takeaways. It almost demands one. So you get: plant-rich diet, low neuroticism, strong social ties, no smoking. All real patterns from the 124 studies. All correlational. None of them tested in a randomized controlled trial on extreme longevity outcomes. Not one.
Jonathan Ingles: Not one RCT. For any of them.
Ben Okonkwo: For extreme longevity specifically — no. Because you can't run that trial. You'd need a fifty-year follow-up, and the endpoint is whether someone reaches a hundred. It's genuinely not feasible. So the entire behavioral evidence base is observational. Which means — actually, wait — this is where the representativeness problem bites hard.
Jonathan Ingles: The populations being studied.
Ben Okonkwo: The Ibrahim review flags it explicitly — centenarian study populations skew toward specific geographic, socioeconomic, and healthcare-access contexts. The New England Centenarian Study is based at Boston University, tracking people who largely had access to consistent medical care over decades. That's not a representative sample of humanity. But when those findings travel into a wellness newsletter, the socioeconomic scaffolding disappears completely.
Jonathan Ingles: Picture this. Someone's at a farmers market in Scottsdale, Arizona — retired, comfortable, good insurance. She reads that centenarians eat plant-rich diets and show high psychological resilience. She buys a hundred-and-twenty-dollar adaptogen supplement. She already has the healthcare access. She already has the low-stress retirement. The olive oil is incidental. The supplement is theater.
Ben Okonkwo: Whereas the mechanism that probably actually matters — consistent preventive screening, no smoking, sustained social connection — those are either free or structurally inaccessible to people without her circumstances. And the review can't tell her that, because the review studied people who largely had her circumstances.
Jonathan Ingles: Which is the move the industry loves. Strip the context, keep the behavior, sell the behavior as the cause.
Ben Okonkwo: Now — the counterposition here, and I want to give it real weight: some researchers genuinely argue that the consistency of these associations across diverse populations is enough to warrant prescriptive guidance. Low neuroticism, plant-rich eating, smoking avoidance — these show up across Japan, Italy, the U.S. That cross-cultural replication isn't nothing.
Jonathan Ingles: No, I don't buy that as a defense of the commercial deployment. Consistent correlation across populations is grounds for a public health message. Not for a personalized longevity protocol sold at a premium.
Ben Okonkwo: That's — yeah, that's the distinction that gets collapsed. Population-level association becomes individual prescription. And the phrase that enables it is exactly what you said earlier: 'no one formula works.' Because that phrase sounds like humility. But it immediately licenses — hm — 'therefore you need a personalized one, tailored to your biology, your genome, your specific markers.'
Jonathan Ingles: The research's own conclusion is the sales hook. Perls and his team find 281 genetic markers and the honest takeaway is — we don't understand this yet. And that becomes: your genome is unique, your protocol should be too, subscribe for forty dollars a month.
Ben Okonkwo: And look — the markers Sebastiani and Perls identified, those 27 signatures — they don't individually predict anything actionable at the consumer level. They're population-level signals in a study of two thousand people. The honest level of certainty there is: we've mapped part of the terrain. Not: here is your personal route through it.
Jonathan Ingles: The Ibrahim review says no universal formula. Plainly. And that's the finding most directly at odds with every commercial application of it. That's not a subtle gap. That's the entire field telling an industry to stop — and the industry quoting the field back at itself.
Ben Okonkwo: And the honest thing to close on here is — the science isn't wrong. The behavioral patterns are real. Smoking avoidance is real. Social connection matters. But the causal arrow is unresolved, the populations are unrepresentative, and no RCT exists. The gap between what the 124 studies actually show and what gets sold on the back of them isn't a communication failure. It's a structural incentive to mistranslate.
Jonathan Ingles: And that's the review's actual gift — Ibrahim's real contribution — clarity about what we cannot promise. We can't tell any individual they'll reach a hundred. We cannot replicate 281 genetic markers with a morning routine. That's not a pessimistic conclusion. That's just the honest one.
Ben Okonkwo: Right — and the science communicated that humility clearly. It's in the paper. It's in the Discover Public Health publication. The media and the wellness industry just found that humility... unprofitable.
Jonathan Ingles: So maybe the honest headline was always — you can't buy your way to a hundred.
Ben Okonkwo: But you might be able to govern your way to a healthier eighty-five. Healthcare access, housing stability, social infrastructure — those are the levers the Ibrahim review's data actually supports at the population level. Not sold in newsletters. Not individualized. Structural.
Jonathan Ingles: Compression of morbidity as a policy goal. Not a personal guarantee.
Ben Okonkwo: That's the one. Modest, specific, and — I mean, actually supported by 55 years of research. Good talk.
